Get startedLog in
    Picture of Egetis Therapeutics AB (publ) logo

    EGTX — Egetis Therapeutics AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    All News

    Brief: Egetis Says FDA's Rare Pediatric Disease Priority Review Program Extended Until 2029

    Picture of Egetis Therapeutics AB (publ) logoEgetis Therapeutics AB (publ)
    04/02/2026 14:28
    Feb 4 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

FDA'S RARE PEDIATRIC DISEASE PRIORITY REVIEW PROGRAM EXTENDED UNTIL 2029

IS ELIGIBLE TO RECEIVE PRIORITY REVIEW VOUCHER (PRV), UPON APPROVAL

Source text: ID:nMFN9JDQMq

Further company coverage: EGTX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Egetis Therapeutics AB (publ)

    See all news